Description: Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life-threatening diseases by stimulating or rebalancing the immune system. Our technology platform is based on two interrelated cytokine drug therapies-Low-Dose Naltrexone (LDN) and Methionine Enkephalin (MENK)-which work by triggering opioid receptors on immune cells to activate various cells of the immune system.
Home Page: www.immunetherapeutics.com
2431 Aloma Avenue
Winter Park,
FL
32792
United States
Phone:
888 613 8802
Officers
| Name | Title |
|---|---|
| Ms. Kelly O'Brien Wilson | Interim CEO & Pres |
| Mr. Glen A. Farmer M.B.A. | Chief Financial Officer |
| Dr. Angus George Dalgleish FMedSci, FRACP, FRCP, FRCPath, M.D. | Chief Medical Officer and Director of R&D |
| Mr. Peter Aronstam Ph.D. | Sec. |
| Dr. Joseph M. Fortunak | VP of Global R&D and Chemical Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 17.0588 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 161.5021 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |